ArborGen FY23: $11.3m working-capital release drove the cash uplift

The headline 1,119.6% revenue change reflects a discontinued-operation overlay in the prior comparable; the company's own commentary describes an 18% revenue increase to US$56.1m and a 35% rise in US-GAAP EBITDA to US$10.3m. PBT turned positive at US$0.9m from a US$0.9m loss (+200.0%), but a 377.8% effective tax rate pulled reported NPAT to a US$2.5m loss versus US$0.1m profit. Net debt almost halved to US$13.0m from US$29.9m, with cash rising to US$12.7m from US$3.9m.

1. The US$11.3m release sits below the historical range (prior periods averaged builds around US$12.8m) and was driven by a 23.7% inventory drawdown to US$31.6m. This matters because run-rate cash generation from earnings alone is closer to US$2–3m than to the reported US$6.5m, and inventory drawdowns are not repeatable indefinitely.

2. Reported growth optics are distorted by the prior-period basis. The 1,119.6% revenue change uses a continuing-operations prior comparable that excludes the divested ANZ business, so the more useful read is management's stated 18% revenue growth and 35% EBITDA growth to US$10.3m. Both represent credible operating progress, but well below the headline arithmetic.

3. Tax is masking the continuing-operations read. PBT growth of 200.0% to US$0.9m is the cleaner operating measure; an effective tax rate of 377.8% pulled NPAT into a US$2.5m loss, and at this scale of pre-tax profit even modest deferred-tax movements dominate the bottom line. ROE sits at -1.7% versus +0.1% prior.

FY23 is heavily second-half weighted: H1 delivered only 13.2% of full-year revenue (US$7.4m of US$56.1m) and a US$1.6m loss, with H2 supplying the implied US$48.7m of revenue and effectively all of the operating swing. Commentary points to record Brazil sales, margin and earnings in H2 plus continued MCP momentum in the US, suggesting the skew reflects strategy execution rather than pure seasonality.

The absence of explicit guidance means investors have limited basis to test whether the FY23 operating improvement extends into FY24 without similar working-capital tailwinds.

On the durable side, PBT turning positive and the company-stated 35% EBITDA growth to US$10.3m point to genuine operating progress, particularly in Brazil. Capex stayed light at 3.9% of revenue, and the balance sheet is materially stronger: gross borrowings fell US$8.1m to US$25.7m and cash rose US$8.8m to US$12.7m, with net debt to EBITDA at roughly 1.3x.

Against that, the cash result is balance-sheet-assisted. The US$11.3m working-capital release explains essentially the entire jump in operating cash flow, and OCF-to-EBITDA at 63.1% would have been materially weaker without it. Pre-lease free cash flow of US$4.3m sits at the upper edge of the historical range (mean US$1.0m) but leans on the same inventory drawdown. FCF-to-NPAT of -172.0% reflects the tax distortion rather than economic weakness. The durable signals are EBITDA growth and lower leverage; the headline cash quality should be treated as partially timing-driven.

This briefing cannot assess management's expectations for FY24 because no forward financial guidance or stated target was disclosed in the release.